Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.30M$2.30Mderived+6.5% vs Q4 2021 Net Income-$2.94M-$2.94MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$96,000N/M Operating Incomederived-$3,061,000N/M Operating Cash Flowderived-$1,395,000N/M Free Cash Flowderived-$1,457,000N/M Margins · derivedGross margin4.2%+13.1 pt vs Q4 2021
Operating margin-133.2%−2.7 pt vs Q4 2021
Net margin-128.1%+41.6 pt vs Q4 2021
ended Mar 31, 2022 · filed Jul 13, 2022 · 104 d after period end